logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

TBEA: The company's transformer has a full order backlog.

date
11/11/2025
China XD Electric announced the Investor Relations Activity Record Form, stating that the company's transformer orders are full, with a normal production cycle of 3-6 months, and delivery is carried out according to customer agreements. The company has orders from North America.
Latest
2 m ago
Central Bank: Expanding and enriching the functions of macro-prudential supervision and financial stability of central banks, innovating financial tools, and maintaining the stable operation of financial markets.
2 m ago
Central Bank: As the importance of an independently controllable supply chain becomes more prominent, the future prospects for accelerating the domestication of core components are optimistic.
2 m ago
Xincheng Development: The contract sales amount in October 2025 is approximately 1.419 billion yuan.
2 m ago
According to a research report released by Open Source Securities on November 10th, Xinghao Pharmaceuticals (920017.SH) was rated as "buy". The reasons for the rating mainly include: 1) From 2025 Q1 to Q3, revenue reached 475 million yuan, a year-on-year increase of 1%, with a net profit attributable to the parent company of 86.25 million yuan, a year-on-year increase of 10%; 2) The orally disintegrating tablets of Sildenafil Citrate (freeze-dried type) have been approved for market launch, and commercial promotion of injectable trypsin has begun; 3) In 2024, the sales of pharmaceuticals in China's three major end markets and six major markets reached 1.8638 trillion yuan, with public hospitals accounting for 60% of the end markets. (Daily Economic News)
2 m ago
According to the AI Fast News of Every Economy, Open Source Securities issued a research report on November 10th, giving DeYuan Pharmaceutical (920735.SH) a "buy" rating. The main reasons for the rating include: 1) Gliclazide sustained-release tablets have received registration certificate, and the first phase of raw material and formulation production complex base is about to be put into operation; 2) The eleventh batch of national centralized procurement adheres to the principles of "stability in clinical practice, quality assurance, prevention of internal turnover, and prevention of circle marking", comprehensively optimizing the rules. (Daily Economic News)
See all latestmore
logo
Contact US
qr
+852 - 60190728
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.